Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|June 29, 2011

PE30Promo

PE 30 Promo

Advertisement
External Link - article-729411.pdf

Advertisement

Related Content

Advertisement
Stock.adobe.com

The Best Use for AI in Drug Development: Q&A with Martin Brenner

ByJoe Petroziello
June 24th 2026
Stock.adobe.com

Eli Lilly and Abbisko Announce Drug Development Collaboration

ByMike Hollan
June 24th 2026
Kyle Smith

How 3D Printing Speeds Up Drug Production

ByMike Hollan,Kyle Smith
June 24th 2026
The intersection of the 340B program with the Inflation Reduction Act (IRA) introduces new complexities in pricing strategy. Credit: Stock.Adobe.com/Yevg45.

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

ByPartha Anbil
June 24th 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

ByMike Hollan
June 23rd 2026
Advertisement
Advertisement

Trending on PharmExec

1

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

2

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

3

FDA Pilot Targets Faster Early-Stage Drug Trial Starts

4

The Next Evolution of Class of Trade: Why Customer Identity Is Becoming Market Access’s Hardest Problem

5

DARPA's Role in Bringing Manufacturing Back to the US

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us